Abstract
The synaptic vesicle protein synaptobrevin (also called VAMP, vesicle-associated membrane protein) forms part of the SNARE (soluble N-ethylmaleimide sensitive factor attachment protein receptor) complex, which is essential for vesicle fusion. Additionally, the synaptobrevin transmembrane domain can promote lipid mixing independently of complex formation. Here, the conformation of the transmembrane domain was studied by using circular dichroism and attenuated total reflection Fourier-transform infrared spectroscopy. The synaptobrevin transmembrane domain has an α-helical structure that breaks in the juxtamembrane region, leaving the cytoplasmic domain unstructured. In phospholipid bilayers, infrared dichroism data indicate that the transmembrane domain adopts a 36° angle with respect to the membrane normal, similar to that reported for viral fusion peptides. A conserved aromatic/basic motif in the juxtamembrane region may be causing this relatively high insertion angle.
Keywords: Fourier-transform infrared spectroscopy, membrane fusion, membrane protein, neuotransmission
In neurons, synaptic vesicles dock at the plasma membrane and fuse upon an increase in local Ca2+ concentration, releasing neurotransmitters into the synaptic cleft (1–3). Many of the proteins involved in this complex reaction have been identified (4–8). Members of the SNARE (soluble N-ethylmaleimide sensitive factor attachment protein receptor) family are involved in the final stages of neurotransmitter release. The binding of the synaptic vesicle protein synaptobrevin to the plasma membrane proteins syntaxin and SNAP-25 is essential for stimulated neurotransmitter release. Although the required factors and precise sequence of events that trigger Ca2+-dependent vesicle fusion is hotly debated, the SNAREs are well established as a fundamental yet incomplete part of the fusion machinery (6).
The neuronal SNARE proteins are largely unstructured as monomers (9–12) and undergo a dramatic structural transition to form an α-helical heterotrimer (13, 14). The energy from this structural transition was proposed to drive membrane fusion (10, 13, 15), but recent studies have shown that SNARE complex formation can occur without inducing fusion (16, 17) and that SNAREs disrupt membranes and promote lipid mixing independent of complex formation (16, 18–20). Thus, the relationship between structure induction, complex formation, and membrane fusion activity remains unclear.
Synaptobrevin (also called VAMP, vesicle-associated membrane protein) contains a single SNARE motif involved in formation of the complex with syntaxin and SNAP-25 and a C-terminal transmembrane domain. The conserved juxtamembrane region (residues 77–90) binds phospholipids and calmodulin (21). Tryptophan residues in the juxtamembrane region cause portions of the SNARE motif to insert into the bilayer (22). These interactions have been suggested to regulate SNARE complex formation and play a role in vesicle fusion (23–25). However, the effect of the transmembrane domain on the structure of the cytosolic domain has been unknown.
Here we used circular dichroism (CD) and attenuated total reflection (ATR) Fourier-transform infrared (IR) spectroscopy (ATR-FTIR) to examine the structure of synaptobrevin in both detergent and phospholipid environments. ATR-FTIR is a well established method for determining the secondary structure and orientation of transmembrane domains (26). The frequency of the amide I absorption depends on the secondary structure, whereas peptide orientation is related to the observed dichroism (27, 28). In addition, site-specific isotopic labeling with 13C shifts the frequency of the vibrational mode, allowing individual residues to be directly probed (29–32).
Results
To study the effect of the transmembrane domain on the structure of synaptobrevin, a series of constructs were used. The full-length construct contained the entire coding sequence for rat synaptobrevin 2 (residues 1–116). The cytoplasmic domain construct was identical to that used for crystallization of the SNARE complex (residues 1–96) (13, 33). However, some of these residues actually insert into the membrane (22). The transmembrane construct contained the predicted transmembrane domain as well as the first 23 aa of the juxtamembrane region (residues 74–116). This construct contained four leucine residues at positions L84, L93, L99 and L107. A series of four peptides corresponding to this sequence were synthesized, each with one leucine residue containing 13C at the carbonyl carbon.
CD Spectroscopy.
Previous studies have shown that the cytoplasmic domain of synaptobrevin is unstructured (9, 11, 12). The synaptobrevin transmembrane domain was proposed to contain a mixture of α-helix and β-sheet, based on IR and CD studies of a 22-aa peptide containing residues 97–112 of the synaptobrevin transmembrane domain flanked by tyrosine and lysine residues (34). To examine the effect of the complete transmembrane domain on the structure of the full-length protein, we analyzed our three synaptobrevin constructs using far-UV CD spectroscopy (Fig. 1 A and B). Spectra were collected in 50 mM β-octyl glucoside (βOG) at identical protein concentrations. Data are reported as molar ellipticity ([θ]ME) rather than mean residue ellipticity because of the disparate lengths of the constructs. The spectrum of the full-length protein showed negative ellipticity at 222 nm and positive ellipticity at 190 nm, indicating some α-helix content (35). The spectrum of the cytoplasmic domain in detergent showed slight negative ellipticity at 222 nm, indicating some α-helical content in agreement with a previous report (11). The transmembrane peptide showed a strong double minima at 208 and 222 nm, both of which are characteristic of α-helical conformation.
Fig. 1.
CD experiments. (A) CD spectra of synaptobrevin constructs in detergent. Full-length synaptobrevin is blue, the cytoplasmic domain is green, and the transmembrane peptide is red. The data are plotted as molar ellipticity [θ]ME (×10−3 °·cm−2·dmol−1) because of the different lengths of the constructs. All spectra were taken at a 100 μM protein concentration in 50 mM βOG. (B) Cartoon illustrating the constructs used in A. The full-length (FL) contained residues 1–116, the cytoplasmic construct (CYT) contained residues 1–96, and the transmembrane construct (TM) contained residues 74–116. The labels are colored according to line colors in A. (C) Sensitivity of secondary structure to detergent for the transmembrane construct at a concentration of 100 μM. The detergent concentrations are five times the reported critical micelle concentrations. The CD spectra were measured in the presence of 13 mM SDS (red), 48 mM cholate (blue), and 95 mM βOG (green). DMPC (1.5 mM) is shown in black. The data are plotted as mean residue ellipticity [θ]MRE (×10−3 °·cm−2·dmol−1 per residue). (D) Effect of increasing of TFE concentration on secondary structure in the transmembrane domain. The transmembrane construct is present at 100 μM with 50 mM βOG. Separate samples were prepared for each spectrum. The CD spectra of the synaptobrevin transmembrane construct are shown without TFE (black), 5% TFE (red), 10% TFE (green), and 30% TFE (blue). The data are plotted as [θ]MRE.
The CD spectra were analyzed to provide information on secondary structure content using cdpro, which has been shown to be successful in estimating the secondary structure of membrane proteins (36, 37). The cytosolic domain contained only 9%, or eight residues, in an α-helical conformation. The 116-residue, full-length protein contained 23% α-helix, which corresponds to 26 residues. The 43-residue peptide contained 63% α-helix, which also corresponds to 26 residues.
The sensitivity of the secondary structure to detergents was tested by comparing the spectra of the transmembrane peptide in anionic (SDS), bile salt (cholate), nonionic (βOG), and lipid-like (dodecylphosphocholine) detergents (Fig. 1C). The mean residue ellipticity, [θ]MRE, of the synaptobrevin transmembrane construct was fairly insensitive to the nature and concentration of the detergent used. The secondary structure of the transmembrane construct was also insensitive to pH over a range of 4–9 (data not shown). To determine whether the peptide could be forced into helical conformation, the CD spectrum of the peptide was taken in the presence of increasing amounts of 2–2-2-trifluoroethanol (TFE), which promotes α-helix formation (Fig. 1D). The α-helical content of the peptide increased to 72% in 5% TFE, 77% in 10% TFE, and 80% in 30% TFE. Thus, even in 30% TFE, an estimated three to four residues remained unstructured.
IR Spectroscopy in Lipid Bilayers.
To examine the conformation of the synaptobrevin transmembrane construct in phospholipid bilayers, we used ATR-FTIR. This technique relies on the correlation between the amide I absorption frequency (predominantly C=O stretching) and the protein secondary structure (26, 27). Four synaptobrevin transmembrane constructs, each containing 13C at the carbonyl carbon of a different leucine residue, were individually reconstituted into 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes at a protein-to-lipid ratio of 1:100. The ATR-FTIR absorption spectra of all four constructs show a predominant absorption centered at 1,655 cm−1, indicative of α-helical conformation (28) (Fig. 2A). The broad amide I absorbance could not be fit to a single peak, so automated peak picking combined with nonlinear least-squares fitting was used to resolve the overlapping peaks in the spectra. All four samples were fit to a four-peak model, resulting in goodness of fit values (X2) ranging from 10−5 to 10−7. Inclusion of additional peaks did not decrease X2. The four peaks are the 1,655 cm−1 band, the corresponding isotopically shifted band, and two absorbances centered at 1,675 cm−1 and 1,635 cm−1 that correspond to extended peptide conformations. A simple comparison of the peak areas averaged over the four peptides predicts 69 ± 3% α-helix (1,655 cm−1), 17 ± 4% anti-parallel β-sheet/β-turn (1,675 cm−1), and 10 ± 3% β-sheet/extended (1,635 cm−1). This estimate is qualitative because the molar absorptivity is thought to differ for different secondary structure types (38). The CD spectra of the peptide indicated the presence of unstructured residues (17% for the peptide), which was not explicitly fit in the IR data analysis. This broad absorbance, 1640–1660 cm−1 (28, 39), overlaps with the helical peak and could therefore contribute to the estimated area of this peak. However, because our data were well fit by the four-peak model described above, the contribution from the unstructured residues cannot be large.
Fig. 2.
IR absorbance experiments. (A) IR absorbance spectra of the amide I region of synaptobrevin transmembrane constructs in POPC bilayers. The labeled constructs contain one leucine residue with 13C at the indicated carbonyl carbon, L84 (green), L93 (red), L99 (magenta), and L107 (blue). The 13C-shifted side peaks are indicated with arrows. (B) Sequence of the synaptobrevin transmembrane construct depicting positions of the labeled 13C leucine residues. The numbering is for rat synaptobrevin 2 (NP_036795). The position of the predicted transition between transmembrane helix and unstructured region is indicated by the star.
The presence of 13C shifts the amide I absorbance frequency by ≈40 cm−1 for the labeled peptide bond (29, 31, 32). Shifted satellite peaks are indeed present in the spectra of the four constructs (Figs. 2 A and B). For the construct labeled at L84, this satellite peak is centered at 1,629 cm−1, a 40-cm−1 shift from a nonhelical region of the spectrum. The other three constructs (L93, L99, and L107) each show a satellite peak centered near 1,615 cm−1, indicative of a 40-cm−1 shift from the α-helical region of the spectrum. Thus, the transmembrane α-helix continues into the polybasic, juxtamembrane region, but this helix does not extend into the cytoplasmic domain in agreement with previous results (22).
We next examined the orientation of the α-helical portion of the transmembrane construct relative to the bilayer using polarized ATR-FTIR. Samples were reconstituted in 1,2 dimyristoyl-sn-glycero-3-phosphocholine (DMPC), which forms a gel-phase bilayer at room temperature. DMPC is commonly used in ATR-FTIR because increased acyl-chain order results in clearer assessment of bilayer orientation with respect to the crystal surface. Representative polarized ATR-FTIR spectra of the constructs illustrating the phospholipid acyl-chain and protein amide I regions of the spectrum are shown in Fig. 3.
Fig. 3.
Representative polarized IR absorbance spectra used to generate order parameters for the tilt angle calculation. The black curve represents absorption of parallel (0°) polarized light. The gray curve represents the absorption of perpendicular (90°) polarized light. The ratio of these absorbances is used to determine RATR. (A) Region of the spectrum corresponding to the lipid acyl-chains for the L99-labeled construct in DMPC. (B) Region of the spectrum corresponding to the protein amide I for the same construct. (C) Region of the spectrum corresponding to the lipid acyl-chains for the L84 labeled construct in POPC. (D) Region of the spectrum corresponding to the protein amide I for the same construct.
The lipid antisymmetric methylene and symmetric methylene stretches were found to be centered at 2,917 cm−1 and 2,849 cm−1, respectively, which is consistent with the deposited bilayer being in the gel phase (40) (Fig. 3A). The dichroic ratio, RATR, of the symmetric methylene stretch, determined from the ratio of absorbance at 0° and 90° polarizations, was 1.1, which results in a calculated lipid order parameter, SL of 0.7. This value is consistent with lipids in the gel phase forming a well ordered deposited bilayer parallel to the crystal surface (28, 41).
The spectra of all four peptides in DMPC were also dominated by the absorption at 1655 cm−1 (Fig. 3B). DMPC samples contained more residual water than samples prepared from POPC, which widened the amide peaks and obscured the 13C-shifted peaks. Estimation of secondary structure by direct comparison of peak area suggests slightly less α-helix in DMPC than POPC, 58 ± 9% at 1,655 cm−1, and similar β-sheet/extended conformation, 12 ± 8% at 1,635 cm−1; whereas the amount of antiparallel β-sheet/β-turn has increased to 29 ± 2% at 1,675 cm−1. These values could indicate the presence of some aggregated peptide.
Only the component of the amide I absorption at 1,655 cm−1 was analyzed for orientation because the nonhelical regions could not be assumed to have a continuous conformation. The RATR of the transmembrane domain was 2.86 ± 0.16 in DMPC. Assuming that the angle between the helix axis and the amide I vibration mode is 39° (42, 43), we calculated a mean value of 0.49 within a range of 0.42–0.56 for the peptide order parameter, SP. If one assumes a continuous α-helix and that the low value for SP results exclusively from a tilt away from the bilayer normal rather than sample disorder, the insertion angle of the transmembrane domain can be derived from SP (Eq. 2). This calculation gives a mean tilt angle of 36° for the synaptobrevin peptide, with a range of 33–39° considering the error in RATR. It is possible that sample disorder (i.e., defects in the deposited bilayer) contributes to the apparent peptide order parameter, resulting in overestimation of the tilt angle. Sample disorder can be estimated from SL, which would approach 1 if the acyl-chains were perfectly ordered, but perfect acyl-chain order would not be expected for a deposited DMPC bilayer at room temperature. Reported SL values for DMPC in the literature are in the range of 0.5–0.8 (28), which is similar to the observed SL of 0.7. Explicit analysis of sample disorder in similar DMPC/peptide samples concluded that sample disorder was not significant (44), but this analysis may not be directly comparable. In any case, our data would not be compatible with a helix perpendicular to the membrane.
Because the gel-phase bilayers formed by DMPC are not likely representative of biological membranes, we also characterized peptide orientation in fluid POPC bilayers. Representative polarized ATR-FTIR spectra of the peptide in POPC showing the phospholipid acyl-chain and protein amide I regions of the spectrum are shown in Fig. 3. The lipid antisymmetric methylene and symmetric methylene stretches of POPC were centered at 2,922 cm−1 and 2,852 cm−1, respectively (Fig. 3C). The positions of these peaks are consistent with the acyl region of the deposited bilayer being in the fluid phase (40), as is expected for POPC at room temperature. The RATR for the symmetric methylene stretch was 1.4, which results in a value of 0.4 for SL. This SL value would be considered low for DMPC but is consistent with liquid–crystalline lipids having an average bilayer orientation perpendicular to the supporting crystal and is in good agreement with SL values reported previously for gel-phase lipids taken above the phase transition temperature (41) and previous studies of POPC (45).
Analysis of the peptide orientation was again limited to the transmembrane α-helix, which was assumed to be continuous (Fig. 3D). We found an average RATR for the transmembrane domain of 1.99 ± 0.04. This gives a value of −0.009 for the SP, which results in a maximum tilt angle of 55° for the peptide relative to the bilayer, assuming that the membranes are perfectly oriented and that the transmembrane domain is a continuous helix. It should be noted that, mathematically, an SP value of zero would also be compatible with an isotropic, random distribution of the peptide orientation relative to the crystal surface. However, given that the bilayers have a mean orientation parallel to the surface and that the hydrophobic peptide is reconstituted in the bilayer, an isotropic distribution is unlikely. The transmembrane domain contains a glycine at residue 100, so it is possible that the transmembrane helix may not be continuous. The 13C-labeled L99 residue, immediately adjacent to G100, and the other transmembrane leucine residues showed strong IR absorption peaks at 1,615 cm−1 (Fig. 2A), indicating a helical conformation. Thus, any helical break would be quite limited. Nonetheless, two helical segments at different orientations could appear as a random distribution of orientation.
Discussion
The sensitivity of neurotransmitter release to proteolytic cleavage of the SNARE proteins by neurotoxins, some of which uncouple the synaptobrevin transmembrane domain from the SNARE motif, highlights the importance of SNARE complex formation in the fusion of synaptic vesicles (13, 46). Studies on vacuolar SNAREs in yeast have shown that the transmembrane domain is necessary for fusion beyond serving as a membrane anchor, because replacement of the transmembrane domain with a gernylgerynl group permits docking and SNARE complex formation but blocks fusion (47). Similarly, amino acid insertions that separate the SNARE motif from the transmembrane domain have a similar effect (48). These results also have been confirmed by using in vitro lipid mixing assays (49), although the relationship of these reactions to fusion in vivo is uncertain (16, 50). Thus, understanding the relationship between the SNARE motif and the transmembrane domain is important to understanding how SNAREs catalyze synaptic vesicle fusion. To this end, we have characterized the structure of full-length synaptobrevin in membrane mimetic environments.
Analysis of the CD spectra of both the full-length protein and a transmembrane domain peptide (residues 73–116) in detergent micelles predicted 26 residues in an α-helical conformation (Fig. 1A). This prediction is in good agreement with analysis of the IR spectra of the transmembrane peptide in lipid bilayers, which predicted 25 and 29 residues in a helical conformation in DMPC and POPC, respectively (Fig. 3). The IR spectra of site-specific, isotopically labeled peptides showed satellite peaks originating from the helical region for leucine residues in the transmembrane domain (L93, L99, and L107) but a satellite peak originating from a wavelength associated with an extended conformation for a residue in the cytoplasmic domain (L84) (Fig. 2A). The site-specific structural information along with the prediction of 25–29 residues in a helical conformation is consistent with an α-helical transmembrane domain that breaks in the polybasic juxtamembrane region as depicted in Fig. 4. Thus, it appears that the transmembrane domain is not sufficient to induce structure in the cytoplasmic domain either in detergents or lipid bilayers.
Fig. 4.
Model of synaptobrevin in a phospholipid bilayer. The transmembrane peptide construct is shown in blue as an idealized α-helix with the break in helical structure predicted from CD and IR spectra. Tryptophan and lysine side chains are shown in stick representation and are displayed in the most favored rotamer positions. A simulated DMPC bilayer is shown for illustration of scale. Bilayer carbon atoms are purple, oxygen atoms are red, and phosphorous atoms are green. The transmembrane domain was placed at a 35° tilt relative to the bilayer normal. The vertical position of the peptide was set by placing the tryptophan residues near the interfacial region of the membrane (22, 59, 62). The model was prepared with pymol (Delano Scientific, San Carlos, CA). (The coordinates for the bilayer were obtained from the Department of Biocomputing at the University of Calgary, Calgary, AB, Canada.)
An extended, rather than helical, conformation for portions of the synaptobrevin transmembrane domain has been proposed (34). Our site-specific labeling results showed that residues L93, L99, and L107 (but not L84) are α-helical, whereas both CD and IR data predicted 25–29 residues in a helical conformation. Our observations are therefore consistent only with an entirely α-helical conformation of the transmembrane domain. This discrepancy may be due to the use of a much shorter peptide in the previous study (34).
By using dichroic IR spectra of oriented multilayers, we calculated a high insertion angle for the synaptobrevin transmembrane domain. In gel-phase DMPC bilayers, the tilt angle was 35°, whereas, in fluid POPC membranes, the tilt angle was 55° with respect to the membrane normal. The difference in measured tilt angles could be due to increased bilayer disorder (relative to the crystal surface) in POPC, which would result in an increase in the apparent angle (51). Our data, in both fluid and gel-phase bilayers, are not compatible with a perpendicular orientation in the bilayer. These tilt angles are high for a single-pass transmembrane domain. Interestingly, this oblique tilt angle is similar to that reported for viral fusion peptides: 50° for HIV (52), 55° for simian immunodeficiency virus (53), and 30–55° for influenza (54, 55). The oblique insertion in viral fusion peptides has been shown to correlate with activity, because mutations that result in parallel or perpendicular membrane association inhibit fusion (56, 57). It has been hypothesized that the oblique insertion angle of viral fusion peptides increases the separation between lipid monolayers, resulting in negative curvature in the outer monolayer, which destabilizes the membrane (56). An oblique angle for the synaptobrevin transmembrane domain may explain the lipid-mixing activity reported recently (16).
EPR studies of synaptobrevin measured a tilt angle of 33° for residues 85–90 but assumed the transmembrane domain to be perpendicular to the membrane (23). Our measurements are in good agreement with this finding and suggest that the insertion angle adopted by the juxtamembrane region continues into the transmembrane domain.
A model of the synaptobrevin transmembrane and juxtamembrane regions is shown in Fig. 4, with tryptophan and lysine side chains shown in most favored rotamer positions. The peptide was placed at the 35° tilt angle measured by IR in DMPC. The synaptobrevin transmembrane domain is relatively short, such that the apolar residues (S115 and T116) cannot protrude from the interior leaflet of the membrane, assuming that the thickness of the bilayer is undisturbed by synaptobrevin or other factors. The observed tilt angle allows the tryptophan side chains to be buried in the bilayer as predicted by EPR studies (22) and allows basic residues to “snorkel” out of the bilayer to interact favorably with the phosphate region of the lipid bilayer (22, 58). The need for snorkeling is particularly evident for K94, which is a full helical turn farther into the bilayer than W90. Interestingly, the relative position of K94 and W90 is strongly conserved in all identified synaptobrevin homologues (Fig. 5). Strong interactions between tryptophan and the interfacial region of the membrane can change bilayer thickness or exclude the peptide from the membrane to satisfy the partitioning requirements (59–62). If synaptobrevin were incorporated with a more perpendicular tilt angle, tryptophan partitioning would cause the lysine residues to be completely buried, which is energetically less favorable (63). Therefore, the conserved residues 89–94 (WWKNLK) may cause the oblique angle of the synaptobrevin transmembrane domain.
Fig. 5.
Alignment of synaptobrevin juxtamembrane region and transmembrane domain. The numbering above the alignment is that of rat synaptobrevin 2. The alignment was performed with clustalw with the PAM 350 matrix (66). The Medline unique identifier is indicated before each sequence followed by the isoform and species information. The image was prepared with espript (67). Residues that are >70% conserved are colored red and highlighted with a blue box.
Materials and Methods
Constructs.
Rat synaptobrevin 2 (residues 1–116) and the isolated cytoplasmic domain (1–96) were expressed by using pet28a (Novagen) in Escherichia coli strain BL21 (DE3) (Novagen). Synthetic peptides corresponding to residues 74–116 of rat synaptobrevin 2 were synthesized by John Flory (W. M. Keck Protein Chemistry Facility, Yale University) using standard N-tert-butoxycarbonyl chemistry. Individual leucine residues were selectively labeled through the incorporation of l-[1-13C]leucine (Cambridge Isotope Laboratories, Andover, MA) at indicated positions. The four peptides behaved identically in purification, electrophoresis, CD, and UV/visual light spectroscopy (data not shown).
Purification.
Purification of full-length synaptobrevin was as described in ref. 64. Briefly, cells were resuspended in 50 mM sodium phosphate/0.5 M NaCl, pH 6.5, with 10 mM 2-mercaptoethanol/20 mM imidazole/Complete EDTA-free tablets (Boeringer Mannheim) added as per manufacturer’s instructions. Thesit was added from a 25% stock to a final concentration of 2%. The supernatant was applied to Ni-NTA agarose (Qiagen, Valencia, CA) and washed with 0.2% Thesit and 40 mM imidazole. For exchange into other detergents, washes of 20 column volumes containing the appropriate detergent were used. Elution was carried out with 250 mM imidazole. Fractions were assessed for purity by SDS/PAGE. Immunoblotting for synaptobrevin was performed from 20% Phast gels (GE Healthcare) according to standard methods with mouse monoclonal antibody clone CL-69.1 (Synaptic Systems, Goettingen, Germany) and developed with ECL (GE Healthcare). The cytoplasmic domain was purified as described in refs. 9 and 33.
The transmembrane construct was purified by reverse-phase HPLC. The aqueous phase was 0.1% (wt/vol) trifluoroacetic acid, and the organic phase was 40% isopropanol, 60% acetonitrile, and 0.1% trifluoroacetic acid. Crude peptides were resuspended in TFE, diluted with 10% organic phase, and loaded onto a C18 semipreparative column (Vydac, Hesperia, CA) equilibrated in 10% organic phase. The peptide was eluted with a linear gradient from 65–85% organic phase. Peptide fractions were assessed by MALDI-TOF MS. Pure fractions were lyophilized and resuspended in TFE. Aqueous samples were prepared by adding transmembrane construct in TFE to detergent solution in water followed by lyophilization and resuspension in the desired buffer.
Reconstitution.
Twelve milligrams of POPC or DMPC in chloroform (Avanti Polar Lipids) was dried to a thin film under argon followed by redrying from pentane to remove any residual chloroform. The lipid was resuspended in 1 ml of deionized water using three rounds of bath sonication (Laboratory Supplies, Hicksville, NY) interspersed with freeze/thaw cycles in liquid nitrogen. The resuspended lipid was added to a lyophilized peptide/detergent mixture resulting in a final peptide lipid ratio of 1:100 and 5% βOG. This synaptobrevin concentration is higher than that reported for synaptic vesicles but does not disrupt membranes (16). This solution was then extensively dialyzed against water containing BioBead SM2 (Bio-Rad) to remove residual detergent. Final dialysis was carried out in 5 mM sodium phosphate/10 mM NaCl at pH 7. Insoluble material was removed by centrifugation for 30 min at 16,000 × g.
CD Spectroscopy.
Far-UV CD spectra were collected on a model 62DS CD spectrometer (Aviv Associates, Lakewood NJ) with 0.1-mm quartz cuvettes at 25°C. All CD spectra represent the average of five scans collected at 1-nm intervals using a 5-s integration time. CD spectra were collected in 10 mM sodium phosphate/50 mM NaCl/1 mM 2-mercaptoethanol at the pH and detergent conditions indicated. Detergents were from Anatrace (Maumee, OH). For determination of molar ellipticity, protein concentrations were determined from the absorbance at 280 nm using a calculated extinction coefficient because all constructs contain the same two tryptophan residues. Spectra were fit with all three methods contained in cdpro, which all gave similar results indicating that the fitting was successful (37). cdpro estimates both regular and distorted α-helix, which were summed to give an estimation of the total amount of α-helix in each construct.
IR Spectroscopy.
For each peptide, deposited bilayers were formed on germanium by spontaneous condensation from reconstituted proteoliposomes in aqueous solution. Reconstituted samples were dried onto the surface of a trapezoidal germanium crystal (dimensions: length, 50 mm; width, 20 mm; depth, 2 mm) using dry air. Spectra were collected at room temperature on a Nicolet Protégé 420 spectrometer equipped with a cooled mercury–cadmium–telluride (MCT/A) detector and extensively purged with nitrogen. The spectrometer was equipped with a 25-reflection variable-angle ATR accessory. For polarized IR spectroscopy, a 0.25-μm wire grid polarizer was used (Grasby Specac, Kent, U.K.). Interferograms (1,000) with a spectral resolution of 1 cm−1 were averaged for each spectrum. Interferograms were processed with omnic 3.1 (Nicolet) by using blank subtraction, 1-level zero-fitting and Happ–Genzel apodization. Overlapping peaks in the spectra were resolved by using the peak-fitting routines within grams/32 (Galactic Industries). Automated peak picking limited to widths of >13 cm−1 was used to identify starting positions for iterative fitting. Fitting was done to mixed Gaussian/Lorentzian line shapes and constrained to positive values within 5 cm−1 of the initial identified peak position. The spectrum of each peptide was recorded three times using separate reconstitutions for each trial. No variation was seen between trials or between different peptides, excluding the wave number of the 13C absorbance. The value of RATR was obtained from the ratio of the areas of the parallel to perpendicular peaks from the fit described above. Assuming the sample to be thicker than the penetration depth of the evanescent wave (thick film), RATR was converted to an order parameter using the following relationship (65):
![]() |
The values for the electric field components of the evanescent wave were Ex = 1.398, Ey = 1.516, and Ez = 1.625 (65). The angle α of the vibrational dipole relative to the molecular axis was 39° for the amide I (42, 43) and 90° for the symmetric methylene (28). The order parameter was used to derive a tilt angle θ by inverting the following relationship (65):
Acknowledgments
We thank L. Fisher and M. Cocco for assistance with peptide purification and IR data collection methodology; S. Arkin for help with IR processing methodology; X. Han for assistance preparing figures; and M. Brzustowicz, P. Strop, and M. Vrljic for helpful comments on the manuscript.
Abbreviations
- ATR
attenuated total reflection
- IR
infrared
- ATR-FTIR
ATR Fourier-transform IR spectroscopy
- βOG
β-octyl glucoside
- TFE
2–2-2-trifluoroethanol
- POPC
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
- DMPC
1,2 dimyristoyl-sn-glycero-3-phosphocholine.
Footnotes
Conflict of interest statement: No conflicts declared.
References
- 1.Calakos N., Scheller R. H. Physiol. Rev. 1996;76:1–29. doi: 10.1152/physrev.1996.76.1.1. [DOI] [PubMed] [Google Scholar]
- 2.Sudhof T. C. Neuron. 2000;28:317–320. doi: 10.1016/s0896-6273(00)00109-4. [DOI] [PubMed] [Google Scholar]
- 3.Sudhof T. C. Annu. Rev. Neurosci. 2004;27:509–547. doi: 10.1146/annurev.neuro.26.041002.131412. [DOI] [PubMed] [Google Scholar]
- 4.Lin R. C., Scheller R. H. Annu. Rev. Cell Dev. Biol. 2000;16:19–49. doi: 10.1146/annurev.cellbio.16.1.19. [DOI] [PubMed] [Google Scholar]
- 5.Chen Y. A., Scheller R. H. Nat. Rev. Mol. Cell Biol. 2001;2:98–106. doi: 10.1038/35052017. [DOI] [PubMed] [Google Scholar]
- 6.Brunger A. T. Q. Rev. Biophys. 2005:1–47. doi: 10.1017/S0033583505004051. [DOI] [PubMed] [Google Scholar]
- 7.Jahn R., Sudhof T. C. Annu. Rev. Biochem. 1999;68:863–911. doi: 10.1146/annurev.biochem.68.1.863. [DOI] [PubMed] [Google Scholar]
- 8.Sudhof T. C. Nature. 1995;375:645–653. doi: 10.1038/375645a0. [DOI] [PubMed] [Google Scholar]
- 9.Fasshauer D., Otto H., Eliason W. K., Jahn R., Brunger A. T. J. Biol. Chem. 1997;272:28036–28041. doi: 10.1074/jbc.272.44.28036. [DOI] [PubMed] [Google Scholar]
- 10.Fiebig K. M., Rice L. M., Pollock E., Brunger A. T. Nat. Struct. Biol. 1999;6:117–123. doi: 10.1038/5803. [DOI] [PubMed] [Google Scholar]
- 11.Hazzard J., Sudhof T. C., Rizo J. J. Biomol. NMR. 1999;14:203–207. doi: 10.1023/a:1008382027065. [DOI] [PubMed] [Google Scholar]
- 12.Rice L. M., Brennwald P., Brunger A. T. FEBS Lett. 1997;415:49–55. doi: 10.1016/s0014-5793(97)01091-0. [DOI] [PubMed] [Google Scholar]
- 13.Sutton R. B., Fasshauer D., Jahn R., Brunger A. T. Nature. 1998;395:347–353. doi: 10.1038/26412. [DOI] [PubMed] [Google Scholar]
- 14.Poirier M. A., Xiao W., Macosko J. C., Chan C., Shin Y. K., Bennett M. K. Nat. Struct. Biol. 1998;5:765–769. doi: 10.1038/1799. [DOI] [PubMed] [Google Scholar]
- 15.Weber T., Zemelman B. V., McNew J. A., Westermann B., Gmachl M., Parlati F., Sollner T. H., Rothman J. E. Cell. 1998;92:759–772. doi: 10.1016/s0092-8674(00)81404-x. [DOI] [PubMed] [Google Scholar]
- 16.Dennison S. M., Bowen M. E., Brunger A. T., Lentz B. Biophys. J. 2006;90:1661–1675. doi: 10.1529/biophysj.105.069617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Bowen M. E., Weninger K., Brunger A. T., Chu S. Biophys. J. 2004;87:3569–3584. doi: 10.1529/biophysj.104.048637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.McNally J. M., Woodbury D. J., Lemos J. R. Cell Biochem. Biophys. 2004;41:11–24. doi: 10.1385/CBB:41:1:011. [DOI] [PubMed] [Google Scholar]
- 19.Liu T., Tucker W. C., Bhalla A., Chapman E. R., Weisshaar J. C. Biophys. J. 2005;89:2458–2472. doi: 10.1529/biophysj.105.062539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Woodbury D. J., Rognlien K. Cell Biol. Int. 2000;24:809–818. doi: 10.1006/cbir.2000.0631. [DOI] [PubMed] [Google Scholar]
- 21.Quetglas S., Leveque C., Miquelis R., Sato K., Seagar M. Proc. Natl. Acad. Sci. USA. 2000;97:9695–9700. doi: 10.1073/pnas.97.17.9695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Kweon D. H., Kim C. S., Shin Y. K. J. Biol. Chem. 2003;278:12367–12373. doi: 10.1074/jbc.M211123200. [DOI] [PubMed] [Google Scholar]
- 23.Kweon D. H., Kim C. S., Shin Y. K. Nat. Struct. Biol. 2003;10:440–447. doi: 10.1038/nsb928. [DOI] [PubMed] [Google Scholar]
- 24.Hu K., Carroll J., Fedorovich S., Rickman C., Sukhodub A., Davletov B. Nature. 2002;415:646–650. doi: 10.1038/415646a. [DOI] [PubMed] [Google Scholar]
- 25.De Haro L., Quetglas S., Iborra C., Leveque C., Seagar M. Biol. Cell. 2003;95:459–464. doi: 10.1016/s0248-4900(03)00076-5. [DOI] [PubMed] [Google Scholar]
- 26.Braiman M. S., Rothschild K. J. Annu. Rev. Biophys. Biophys. Chem. 1988;17:541–570. doi: 10.1146/annurev.bb.17.060188.002545. [DOI] [PubMed] [Google Scholar]
- 27.Goormaghtigh E., Cabiaux V., Ruysschaert J. M. Subcell. Biochem. 1994;23:405–450. doi: 10.1007/978-1-4615-1863-1_10. [DOI] [PubMed] [Google Scholar]
- 28.Tamm L. K., Tatulian S. A. Q. Rev. Biophys. 1997;30:365–429. doi: 10.1017/s0033583597003375. [DOI] [PubMed] [Google Scholar]
- 29.Anderson T. S., Hellgeth J., Lansbury P. T. J. Am. Chem. Soc. 1996;118:6540–6546. [Google Scholar]
- 30.Arkin I. T., MacKenzie K. R., Brunger A. T. J. Am. Chem. Soc. 1997;119:8973–8980. [Google Scholar]
- 31.Ludlam C. F., Arkin I. T., Liu X. M., Rothman M. S., Rath P., Aimoto S., Smith S. O., Engelman D. M., Rothschild K. J. Biophys. J. 1996;70:1728–1736. doi: 10.1016/S0006-3495(96)79735-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Tadesse L., Nazarbaghi R., Walters L. J. Am. Chem. Soc. 1991;113:7036–7037. [Google Scholar]
- 33.Fasshauer D., Eliason W. K., Brunger A. T., Jahn R. Biochemistry. 1998;37:10354–10362. doi: 10.1021/bi980542h. [DOI] [PubMed] [Google Scholar]
- 34.Langosch D., Crane J. M., Brosig B., Hellwig A., Tamm L. K., Reed J. J. Mol. Biol. 2001;311:709–721. doi: 10.1006/jmbi.2001.4889. [DOI] [PubMed] [Google Scholar]
- 35.Fasman G. D. Circular Dichroism and the Conformational Analysis of Biomolecules. New York: Plenum; 1996. [Google Scholar]
- 36.Sreerama N., Woody R. W. Anal. Biochem. 2000;287:252–260. doi: 10.1006/abio.2000.4880. [DOI] [PubMed] [Google Scholar]
- 37.Sreerama N., Woody R. W. Protein Sci. 2004;13:100–112. doi: 10.1110/ps.03258404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.de Jongh H. H., Goormaghtigh E., Ruysschaert J. M. Anal. Biochem. 1996;242:95–103. doi: 10.1006/abio.1996.0434. [DOI] [PubMed] [Google Scholar]
- 39.Jackson M., Mantsch H. H. Crit. Rev. Biochem. Mol. Biol. 1995;30:95–120. doi: 10.3109/10409239509085140. [DOI] [PubMed] [Google Scholar]
- 40.Mantsch H. H., Mcelhaney R. N. Chem. Phys. Lipids. 1991;57:213–226. doi: 10.1016/0009-3084(91)90077-o. [DOI] [PubMed] [Google Scholar]
- 41.Okamura E., Umemura J., Takenaka T. Biochim. Biophys. Acta. 1990;1025:94–98. doi: 10.1016/0005-2736(90)90195-t. [DOI] [PubMed] [Google Scholar]
- 42.Miyazawa T., Blout E. R. J. Am. Chem. Soc. 1961;83:712–719. [Google Scholar]
- 43.Tsuboi M. J. Polymer Sci. 1962;59:139–153. [Google Scholar]
- 44.Manor J., Khattari Z., Salditt T., Arkin I. T. Biophys. J. 2005;89:563–571. doi: 10.1529/biophysj.104.058842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Frey S., Tamm L. K. Biophys. J. 1991;60:922–930. doi: 10.1016/S0006-3495(91)82126-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B. R., Montecucco C. Nature. 1992;359:832–835. doi: 10.1038/359832a0. [DOI] [PubMed] [Google Scholar]
- 47.Grote E., Baba M., Ohsumi Y., Novick P. J. J. Cell Biol. 2000;151:453–466. doi: 10.1083/jcb.151.2.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Wang Y., Dulubova I., Rizo J., Sudhof T. C. J. Biol. Chem. 2001;276:28598–28605. doi: 10.1074/jbc.M101644200. [DOI] [PubMed] [Google Scholar]
- 49.McNew J. A., Weber T., Parlati F., Johnston R. J., Melia T. J., Sollner T. H., Rothman J. E. J. Cell Biol. 2000;150:105–117. doi: 10.1083/jcb.150.1.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Chen X., Arac D., Wang T. M., Gilpin C. J., Zimmerberg J., Rizo J. Biophys. J. 2006;90:2062–2074. doi: 10.1529/biophysj.105.071415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Arkin I. T., Rothman M., Ludlam C. F., Aimoto S., Engelman D. M., Rothschild K. J., Smith S. O. J. Mol. Biol. 1995;248:824–834. doi: 10.1006/jmbi.1995.0263. [DOI] [PubMed] [Google Scholar]
- 52.Martin I., Schaal H., Scheid A., Ruysschaert J. M. J. Virol. 1996;70:298–304. doi: 10.1128/jvi.70.1.298-304.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Bradshaw J. P., Darkes M. J., Harroun T. A., Katsaras J., Epand R. M. Biochemistry. 2000;39:6581–6585. doi: 10.1021/bi000224u. [DOI] [PubMed] [Google Scholar]
- 54.Han X., Steinhauer D. A., Wharton S. A., Tamm L. K. Biochemistry. 1999;38:15052–15059. doi: 10.1021/bi991232h. [DOI] [PubMed] [Google Scholar]
- 55.Luneberg J., Martin I., Nussler F., Ruysschaert J. M., Herrmann A. J. Biol. Chem. 1995;270:27606–27614. doi: 10.1074/jbc.270.46.27606. [DOI] [PubMed] [Google Scholar]
- 56.Martin I. I., Ruysschaert J., Epand R. M. Adv. Drug Delivery Rev. 1999;38:233–255. doi: 10.1016/s0169-409x(99)00031-9. [DOI] [PubMed] [Google Scholar]
- 57.Epand R. F., Martin I., Ruysschaert J. M., Epand R. M. Biochem. Biophys. Res. Commun. 1994;205:1938–1943. doi: 10.1006/bbrc.1994.2897. [DOI] [PubMed] [Google Scholar]
- 58.Mishra V. K., Palgunachari M. N., Segrest J. P., Anantharamaiah G. M. J. Biol. Chem. 1994;269:7185–7191. [PubMed] [Google Scholar]
- 59.Yau W. M., Wimley W. C., Gawrisch K., White S. H. Biochemistry. 1998;37:14713–14718. doi: 10.1021/bi980809c. [DOI] [PubMed] [Google Scholar]
- 60.Ridder A. N., Morein S., Stam J. G., Kuhn A., de Kruijff B., Killian J. A. Biochemistry. 2000;39:6521–6528. doi: 10.1021/bi000073v. [DOI] [PubMed] [Google Scholar]
- 61.de Planque M. R., Goormaghtigh E., Greathouse D. V., Koeppe R. E., II, Kruijtzer J. A., Liskamp R. M., de Kruijff B., Killian J. A. Biochemistry. 2001;40:5000–5010. doi: 10.1021/bi000804r. [DOI] [PubMed] [Google Scholar]
- 62.de Planque M. R., Kruijtzer J. A., Liskamp R. M., Marsh D., Greathouse D. V., Koeppe R. E., II, de Kruijff B., Killian J. A. J. Biol. Chem. 1999;274:20839–20846. doi: 10.1074/jbc.274.30.20839. [DOI] [PubMed] [Google Scholar]
- 63.Hessa T., Kim H., Bihlmaier K., Lundin C., Boekel J., Andersson H., Nilsson I., White S. H., von Heijne G. Nature. 2005;433:377–381. doi: 10.1038/nature03216. [DOI] [PubMed] [Google Scholar]
- 64.Bowen M. E., Engelman D. M., Brunger A. T. Biochemistry. 2002;41:15861–15866. doi: 10.1021/bi0269411. [DOI] [PubMed] [Google Scholar]
- 65.Harrick N. J. Internal Reflection Spectroscopy. New York: Interscience; 1967. [Google Scholar]
- 66.Chenna R., Sugawara H., Koike T., Lopez R., Gibson T. J., Higgins D. G., Thompson J. D. Nucleic Acids Res. 2003;31:3497–3500. doi: 10.1093/nar/gkg500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Gouet P., Courcelle E., Stuart D. I., Metoz F. Bioinformatics. 1999;15:305–308. doi: 10.1093/bioinformatics/15.4.305. [DOI] [PubMed] [Google Scholar]






